Purchase Order 75N93025P00016
Award Date
10/18/24
Potential Completion Date
3/14/25
Potential Value
$14K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Seqcenter LLC
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
ARSENAL, PA 15201, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, awarded a $10,650.00 firm fixed-price purchase order contract to Scale Biosciences, Inc. for the procurement of RNA kits. This contract has a total small business set-aside designation and a period of performance through December 31, 2024. As NIAID is responsible for conducting and supporting research to understand, treat, and prevent infectious diseases, this contract award is likely related to their...
This federal contract award is for the purchase of one (1) Illumina NextSeq 2000 sequencing system and a 12-month service plan by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The $390,644 firm fixed-price contract was awarded to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is a base plus one (1) option period, with a final completion...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Illumina, Inc., a for-profit manufacturer of genetic sequencing instruments and reagents. The $3,938.22 firm fixed price purchase order is for the delivery of sequencing kits, with a completion date of September 14, 2015. The contract has no set-aside designation. Illumina has a history of providing sequencing systems, reagents, and...
This is a $14,997.46 firm fixed price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Illumina, Inc., a for-profit manufacturer of genetic analysis instruments and reagents. The contract is not set aside for any specific business size or type. Under this award, Illumina will provide a range of its NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, as well as accompanying reagents, consumables, sample preparation kits,...
This is a $14,400.00 firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Personal Diagnostix Inc., a minority-owned and small disadvantaged business, for Ion Torrent sequencing of RNA virus samples. The contract has an ultimate completion date of April 25, 2013 and does not have a set-aside designation. This contract appears to be for NIAID's research and development activities related to viral diagnostics...
The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of sequencing and array-based solutions, for the NextSeq 1000 Sequencing System. The $213,150.00 contract supports NIAID's Vaccine Immunology Program's research into monoclonal antibodies and vaccines for infectious diseases such as HIV, influenza, Ebola, and SARS-CoV-2....
The Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm fixed price purchase order to Illumina, Inc., a for-profit manufacturer of genomic sequencing systems and reagents. The $101,340.96 contract provides a one-year service plan for Illumina's NextSeq and MiSeq sequencing platforms, as well as an iSeq 100 system, to be used at an NIAID facility in Frederick, Maryland. The contract was...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm fixed-price purchase order to Novogene Corp Inc., a minority-owned small business, for RNA sequencing services. The $13,410.00 contract has a completion date of June 30, 2024. Novogene is a provider of next-generation sequencing technologies and has delivered sequencing and bioinformatics services to support biomedical research across various federal...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm-fixed-price purchase order to Pacific Biosciences of California, Inc. for $104,800.00 to provide a SHORT-READ NEXT GENERATION SEQUENCING PLATFORM (ONSO SYSTEM). The contract does not have a set-aside designation and is for the delivery of Pacific Biosciences' Sequel and Sequel II DNA/RNA sequencing platforms, associated consumables, and related services. This award is part of a larger $13.5 million single-award...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to Illumina, Inc. for a Next Generation Sequencing System and Support Plan. The contract has a period of performance from September 29, 2025 to September 28, 2026 and a ceiling value of $249,999.58. The contract was awarded under a sources sought notice that was not set aside for any particular business type. The sequencing system will be...